Your Cart is Empty
Cellecta provides a Next-Generation Sequencing (NGS) human leukocyte antigen (HLA) typing solution, which uses the capabilities of hybrid capture technology. This dynamic workflow eliminates the inefficiencies and limitations associated with traditional Long-Range PCR methods.
The assay employs a clinically validated AlloSeq™ Tx workflow starting with genomic DNA. It begins by preparing a whole genome library using bead-bound transposons. Each sample is then indexed and pooled into a single tube. Biotinylated probes capture the genes of interest, enriching them for sequencing on an Illumina system. The resulting data is analyzed using the AlloSeq Assign software solution.
The interaction between foreign antigens and T cells is facilitated by protein complexes called Major Histocompatibility Complexes (MHC), encoded by HLA genes. HLA type significantly influences T-cell selection and the composition of T-cell receptor (TCR) repertoires.
Cellecta offers a TCR profiling service with its DriverMap™ Adaptive Immune Receptor (AIR) Repertoire technology that profiles all TCR- alpha, beta, gamma, and delta chains in a single multiplex RT-qPCR reaction. Combined immune receptor profiling and HLA typing can provide valuable insights into the human immune system and potentially improve patient outcomes by enabling more personalized treatment options. The assay is for Research Use Only (RUO).
AlloSeq is a trademark of CareDx. All other trademarks are property of their respective owners.
